

AMENDMENTS TO THE CLAIMS

This listing replaces all versions and listings of claims in the application.

Listing of Claims

1 - 63. (Cancelled).

64. (Currently Amended) A composition for the treatment of dermal inflammation, comprising a combination of

- (i) glyceryl monocaprylate or an alkali metal salt thereof and
- (ii) niacinamide or a salt thereof,

wherein the component (i) and the component (ii) are present in a molar ratio of between about 1:3 and 1:16.

65-71. (Cancelled).

72. (Previously Presented) The composition according to claim 64, wherein the component (i) is racemic, enantiomerically enriched or enantiomerically pure 1-glyceryl-monocaprylate and wherein component (ii) is niacinamide.

73. (Currently Amended) The composition according to claim 64, further comprising one or more excipient(s) or carrier(s) for the formulation of a pharmaceutical, a dietary supplement or a cosmetic.

74. (Previously Presented) The composition according to claim 73, further comprising one or more therapeutically active agents.

75. (Currently Amended) The composition according to claim 73, formulated for oral, topical, or transdermal, or parenteral administration.

76. (Previously Presented) The composition according to claim 75, formulated for topical administration.

77-93. (Cancelled)

94. (Currently Amended) The composition according to claim 72, wherein the 1-glyceryl monocaprylate and the niacinamide[[,]] or a salt thereof, are present in a molar ratio of between about 1:14 to 14:1 or about 2:7.

95-96. (Cancelled)